Wells Fargo & Company Cuts Teleflex (NYSE:TFX) Price Target to $114.00

Teleflex (NYSE:TFX) had its target price decreased by Wells Fargo & Company from $131.00 to $114.00 in a research note released on Friday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the medical technology company’s stock.

TFX has been the topic of several other research reports. Zacks Research downgraded Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Wall Street Zen downgraded Teleflex from a “strong-buy” rating to a “buy” rating in a report on Monday, September 15th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Teleflex in a research report on Wednesday, October 8th. Mizuho increased their target price on shares of Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. Finally, Royal Bank Of Canada reduced their target price on Teleflex from $135.00 to $120.00 and set a “sector perform” rating on the stock in a report on Friday. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $137.00.

Teleflex Price Performance

NYSE:TFX opened at $109.20 on Friday. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42. Teleflex has a 12-month low of $102.58 and a 12-month high of $200.15. The stock’s 50 day moving average price is $125.66 and its two-hundred day moving average price is $123.00. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of 25.70, a P/E/G ratio of 1.79 and a beta of 1.05.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, November 6th. The medical technology company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $3.38 by $0.29. The business had revenue of $892.90 million for the quarter, compared to analysts’ expectations of $892.79 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The firm’s revenue for the quarter was up 19.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.49 EPS. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. On average, analysts anticipate that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Friday, November 14th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Friday, November 14th. Teleflex’s dividend payout ratio (DPR) is currently -18.50%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. MassMutual Private Wealth & Trust FSB lifted its position in shares of Teleflex by 57.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 77 shares in the last quarter. Thompson Investment Management Inc. raised its stake in shares of Teleflex by 2.1% during the 2nd quarter. Thompson Investment Management Inc. now owns 4,970 shares of the medical technology company’s stock valued at $588,000 after purchasing an additional 100 shares during the period. CX Institutional boosted its stake in Teleflex by 14.7% in the 2nd quarter. CX Institutional now owns 872 shares of the medical technology company’s stock worth $103,000 after purchasing an additional 112 shares during the period. Signaturefd LLC boosted its stake in Teleflex by 38.3% in the 1st quarter. Signaturefd LLC now owns 433 shares of the medical technology company’s stock worth $60,000 after purchasing an additional 120 shares during the period. Finally, Empirical Finance LLC increased its position in shares of Teleflex by 7.9% during the first quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company’s stock valued at $234,000 after buying an additional 124 shares during the period. 95.62% of the stock is owned by institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.